Dosage Guide

Tesamorelin Dosage Guide

Everything you need to correctly dose, reconstitute, and administer Tesamorelin. If you’re new to this peptide, start with the Quickstart below.

Free Download – The #1 Reference Guide

The Ultimate Peptide Blueprint

Exact stacks, dosages & protocols for 20+ peptides. The complete reference for free.

Reconstitute

3.0mL bacteriostatic water

3.33 mg/mL

Daily Range

2 MG

Once daily (gradual titration)

Storage

Lyophilized: Freeze at−20 °C (−4 °F)

After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 1–2 weeks.

Free Download

Want the Complete Stack?

Tesamorelin stacking protocols alongside 20+ other peptides. Fat loss, recovery, longevity. All in one free guide.

Quickstart Highlights

Tesamorelin, also known by its FDA-approved brand name Egrifta, is a synthetic peptide designed to mimic the body’s natural growth hormone–releasing hormone (GHRH). Its primary function is to stimulate the pituitary gland to increase the release of growth hormone, a key regulator of metabolic activity, fat distribution, and overall physiological balance.

Tesamorelin was originally approved for the treatment of HIV-associated lipodystrophy, a condition characterized by excess accumulation of abdominal fat. Since then, it has drawn broader research interest due to its targeted effects on visceral fat, the metabolically active fat stored around internal organs that is closely linked to cardiometabolic risk.

Because of this selective action, Tesamorelin continues to be studied for its role in body composition, metabolic regulation, and hormone-mediated pathways beyond its initial clinical indication.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)z

Week 1

Daily Dose: 1 MG (1,000 mcg)

30 units

Week 2–12 and beyond

Daily Dose: 2mg (2,000 mcg)

60 units

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly to avoid foaming.
Gently swirl or roll the vial until powder fully dissolves (do not shake vigorously).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important

This guide is for educational purposes only and is not medical advice. For research use only. Not for human or animal use. LAB ONLY.

Dosing Overview

Suggested daily titration approach.

Week 1 (Titration): 1 mg (1,000 mcg) once daily to evaluate individual tolerance.
Weeks 2 and Beyond: 2 mg (2,000 mcg) once daily, representing the standard FDA-approved maintenance dose.
Frequency: Administer once per day via subcutaneous injection, with evening dosing commonly preferred.
Treatment Length: Typical courses range from 12–26 weeks, with clinical data supporting extension up to 52 weeks when appropriately monitored.

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Designed to decrease visceral adipose tissue and support healthier lipid markers through sustained elevation of GH and IGF-1 signaling.
Administration Plan: Subcutaneous dosing performed daily for 12–26 weeks, with evidence supporting continuation for up to 52 weeks under medical supervision.
Dosing Protocol: 2 mg (2,000 mcg) daily following an initial one-week titration phase.
Preparation Standard: Reconstitute each 10 mg vial with 3.0 mL, yielding an approximate concentration of 3.33 mg/mL for precise dosing.
Storage: Store lyophilized material frozen. After reconstitution, refrigerate and avoid repeated freeze–thaw cycles.

Storage Instructions

Proper storage preserves peptide quality and potency.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; keep in original packaging to minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks for optimal potency.
Avoid Freeze–Thaw: Do not refreeze reconstituted solution; freeze–thaw cycles denature peptides.
Allow lyophilized vials to reach room temperature before opening to reduce condensation.

Free Download – Complete Peptide Reference

The Ultimate Peptide Blueprint

Stacking guides, advanced cycles, longevity protocols, and dosing for 20+ peptides. All in one free guide.

Supplies Needed

How Tesamorelin Works in the Body

Tesamorelin functions by closely replicating the body’s own growth hormone–releasing hormone (GHRH). After administration, it binds to GHRH receptors in the pituitary gland, signaling the release of endogenous growth hormone (GH).

Once GH enters circulation, it prompts the liver to produce insulin-like growth factor 1 (IGF-1). IGF-1 plays a central role in regulating tissue growth, metabolic activity, and fat utilization. This downstream cascade is what makes Tesamorelin particularly effective in research related to visceral fat reduction while helping preserve lean tissue.

Unlike short-acting compounds that cause brief spikes in growth hormone, Tesamorelin provides a sustained signaling effect. This longer duration leads to more stable GH and IGF-1 levels over time, which has been associated in studies with improved metabolic markers and, in some cases, enhanced recovery and sleep quality.

Rather than delivering a sudden surge, Tesamorelin offers a steady hormonal signal—an approach that supports more gradual, consistent, and potentially sustainable outcomes.

Tesamorelin Side Effects

Understanding how Tesamorelin is commonly approached in research settings—along with its safety considerations—helps support informed and responsible use.

Dosage Guidelines

A conservative approach works best: begin at a lower dose and increase only if well tolerated.

Across clinical references and research protocols, Tesamorelin dosing follows relatively consistent patterns. The most frequently cited research dose is 300 mcg administered subcutaneously, typically on a 5-days-on / 2-days-off schedule. Common cycle structures involve 8 weeks of use followed by an 8-week break, or discontinuation once study objectives are met.

Example Dosing Approaches

Introductory Protocol

150 mcg nightly, subcutaneous
5 days on / 2 days off
Intended for first-time users or those seeking a lower-intensity introduction
Monitor sleep quality, energy levels, and fasting glucose

Standard Research Protocol

300 mcg nightly, subcutaneous
5 days on / 2 days off
Often administered 60–90 minutes after the final meal, aligning with natural growth hormone rhythms
Monitoring recommendation: establish baseline fasting glucose and IGF-1, then reassess periodically

Advanced / Targeted Fat Research (supervised use only)

1–2 mg nightly, 5 days on / 2 days off
Cycle length: 10–12 weeks, followed by an extended off-period
This higher-dose approach appears in select practice-based protocols focused on visceral fat, but should only be considered with medical oversight and frequent laboratory monitoring

Safety Overview

Tesamorelin is generally well tolerated when dosing is approached thoughtfully and monitored consistently.

Best practices include:

Completing a full 8-week on-cycle comfortably is often more valuable than escalating too quickly. After completing a cycle, an 8-week off-period allows physiological systems to reset. When beginning a subsequent cycle, starting slightly below the prior ending dose may help ease re-adaptation.

Commonly Reported Side Effects

Some individuals may experience mild, temporary effects during use, particularly early in a cycle:

Injection site reactions: Mild redness, itching, or swelling; rotating sites helps reduce irritation
Muscle or joint discomfort: Typically mild and transient; may be dose-dependent
Digestive symptoms: Occasional nausea or loose stools; adequate hydration and dose adjustment may help
Headache, fatigue, or sweating: Often short-lived as the body adapts
Metabolic changes: Mild increases in fasting glucose have been reported—regular monitoring is advised

Less Common but Important Risks

Although uncommon, certain effects warrant closer attention.

Insulin Resistance

Tesamorelin can increase insulin resistance in some individuals. That means blood sugar can rise even if you are following the same diet and activity plan.

Why this happens, in plain terms:

Growth hormone signals the body to mobilize energy, which can raise blood sugar in the short term.
Some individuals are more sensitive to this effect, especially if they already have impaired glucose control.

How to monitor and what to do:

Test fasting blood glucose first thing in the morning with a home glucometer. Do this at baseline, again at 2 to 4 weeks after starting, then every 4 weeks while on the cycle, and once more a few weeks after stopping.
Get an HbA1c at baseline and then every 2 to 3 months if you continue treatment. Record results and compare them to your baseline.
Watch for a fasting glucose rise of more than 20 mg/dL above your baseline, or an HbA1c increase of more than 0.5 percentage points. These are signals to pause or lower dose and recheck.

Note: If fasting glucose climbs into the diabetic range (above 125 mg/dL) or HbA1c reaches 6.5% or higher, stop the protocol immediately and consult a clinician. It may also be wise to pause earlier if you see steady increases or symptoms like excessive thirst or frequent urination. If you have diabetes or prediabetes, talk to your doctor before using Tesamorelin.

Fluid Retention and Edema

Growth hormone activity can sometimes cause the body to hold on to extra salt and water. People with heart failure, kidney disease, or poorly controlled blood pressure are more likely to notice this.

What to watch for:

New swelling in the ankles or legs
Rapid weight gain, for example, more than 2 kg (about 4.5 lb) in 48 to 72 hours
Shortness of breath or difficulty breathing

If you see these signs, stop dosing and seek medical evaluation. Keep a weekly weight log while on treatment so you can spot sudden changes early.

Pituitary Related Concerns

Because Tesamorelin stimulates the pituitary gland, people with known pituitary tumors or prior pituitary surgery could be at higher risk for changes in pituitary function or pressure.

Red flags to stop immediately and seek urgent care:

New, severe headaches that are different from your usual headaches
Vision changes, such as blurring or loss of peripheral vision
Repeated vomiting or sudden confusion

If you have a known pituitary condition, discuss risks with a specialist before starting Tesamorelin.

Bottomline

Rare but serious events are uncommon, but they are important to recognize early. Track your daily observations, test fasting glucose regularly, weigh yourself weekly, and report any worrying trends. If fasting glucose exceeds 125 mg/dL or HbA1c reaches 6.5% or higher, stop dosing and contact your clinician right away. For other serious signs, such as sudden swelling with breathlessness or new severe headaches and vision changes, stop immediately and seek urgent medical attention.

Important Notes

Proper storage preserves peptide quality and potency.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) daily to reduce local irritation and lipohypertrophy.
Inject slowly and steadily; wait a few seconds before withdrawing the needle to prevent leakage.
Document daily dose, injection site, and any subjective effects (cognition, mood, sleep) to track response.
For doses under 10 units (Week 1–2: 9 units), consider 30‑ or 50‑unit insulin syringes for better precision.

Important

This guide is for educational purposes only and is not medical advice. For research use only. Not for human or animal use. LAB ONLY.

Joe Mars

Founder, The Peptide Report

I’m Joe Mars, and I’ve dedicated the past ten years to understanding peptide therapy, longevity, and how to optimize the body through practical, real-life testing. My journey started when I was tired, inflamed, and aging faster than I should have been. Clear information on peptides was almost impossible to find, so I dug in, researched nonstop, and tested protocols on myself.

Over the years, I have learned from experts like Jay Campbell, Dr. Seeds, Jim LaValle, and Ben Greenfield, and I have completely transformed my health. Now in my fifties, I feel stronger and sharper than I did in my twenties. That experience is why I write. I want to give people simple and honest guidance so they can use peptides safely and effectively.

I believe in data, smart protocols, and taking responsibility for your own health. You are the protocol. Your habits, your consistency, and your awareness shape your results. Through The Peptide Report, I share what actually works so you can make informed decisions and build a healthier, more resilient body.